Cristian F. RodríguezPaula Guzmán-SastoqueAlan Santacruz-BelalcazarC. Jorge Laureano Moya RodríguezPaula VillamarinLuis H. ReyesJuan C. Cruz2026-03-222026-03-22202510.1080/17425247.2025.2506829https://doi.org/10.1080/17425247.2025.2506829https://andeanlibrary.org/handle/123456789/85718Citaciones: 6While magnetoliposomes show remarkable therapeutic versatility, their clinical translation requires addressing biocompatibility concerns, manufacturing scalability, and regulatory hurdles. Integration with artificial intelligence, organ-on-chip technologies, and personalized medicine approaches will likely accelerate their development toward clinical reality, potentially revolutionizing treatment paradigms for complex diseases through tailored therapeutic interventions.enNanomedicineDrug deliveryNanotechnologyDrugGene deliveryMaterials sciencePeptideTargeted drug deliveryPharmacologyMedicinereview